All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154253" target="_blank" >RIV/61989592:15110/15:33154253 - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15510/15:33154253 RIV/00098892:_____/15:#0000924

  • Result on the web

    <a href="http://dx.doi.org/10.4149/neo_2015_074" target="_blank" >http://dx.doi.org/10.4149/neo_2015_074</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4149/neo_2015_074" target="_blank" >10.4149/neo_2015_074</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center

  • Original language description

    This study aimed at mapping the frequency of IGHV3-21 and IGHV1-69 in a group of 417 patients newly diagnosed with chronic lymphocytic leukemia (CLL) and described basic characteristics, cytogenetic abnormalities and prognosis of these patient subgroups.IGHV3-21 was found in 29 patients (7%) and IGHV1-69 in 51 patients (12.4%). The median overall survival (OS) rates were 97 months and 85 months in the IGHV3-21 and IGHV1-69 groups, respectively. In this small group of patients, the study failed to showa difference in OS of IGHV3-21 patients with mutated and unmutated IGHV status (p<0.597). There was also no difference in OS between IGHV3-21 patients with mutated IGHV status and all patients in the group having unmutated IGHV status (p<0.245). On the other hand, patients with IGHV3-21 and the presence of some other adverse prognostic factors (age GREATER-THAN OR EQUAL TO 65 years, lymphocyte count GREATER-THAN OR EQUAL TO 50x109/L, serum thymidine kinase GREATER-THAN OR EQUAL TO 9U/L,

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Neoplasma

  • ISSN

    0028-2685

  • e-ISSN

  • Volume of the periodical

    62

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    SK - SLOVAKIA

  • Number of pages

    9

  • Pages from-to

    618-626

  • UT code for WoS article

    000362862500013

  • EID of the result in the Scopus database